&nbsp;

Drugs Used:

abemaciclib,

exemestane

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

ABEMTMXF

Cancer Type:

Breast

Intent: Adjuvant

Funding:

Exceptional Access Program

ODB - General Benefit

tamoxifen

Drugs Used:

abemaciclib,

tamoxifen

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

BELZ

Cancer Type:

Endocrine,

Pancreatic Neuroendocrine,

Genitourinary,

Renal cell / Kidney

Intent: Curative, Palliative

Funding:

Exceptional Access Program

Belzutifan – For the treatment of adult patients with von Hippel-Lindau (VHL) disease, based on criteria

Drugs Used:

belzutifan

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DARO(MNT)

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel

Drugs Used:

darolutamide

Quick Link(s):

Regimen Monograph

Aug 2025

Drug

fedratinib

Other Name(s): Inrebic®

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jul 2025

Regimen

SELP

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Funding:

Exceptional Access Program

selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)

Drugs Used:

selpercatinib

Quick Link(s):

Regimen Monograph

Apr 2025

Regimen

IBRUVENE

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria

Exceptional Access Program

venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria

Drugs Used:

iBRUtinib,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

ABIRNIRPPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

niraparib / abiraterone - For the treatment of metastatic castration resistant prostate cancer in patients with a BRCA mutation

ODB - General Benefit

prednisone

Drugs Used:

niraparib / abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

CISPPEME+OSIM

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

CRBPPEME+OSIM

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

PEME+OSIM(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria

Drugs Used:

pemetrexed,

osimertinib